光大同創(301387.SZ):已將碳纖維產品應用於外骨骼機器人結構件中
格隆匯5月9日丨光大同創(301387.SZ)在投資者互動平臺表示,目前公司暫未與上述企業開展合作。在全球產業升級的背景下,輕量化已成爲消費電子、機器人、醫療設備等多個行業的重要發展趨勢。作爲輕量化材料的理想選擇,碳纖維材料正迎來廣闊的市場機遇,這也正是公司戰略佈局的核心方向。在機器人領域,碳纖維結構件憑藉其優異的減重性能,能顯著提升機器人的運動靈活性和能效表現。公司已將碳纖維產品應用於外骨骼機器人結構件中,公司密切關注行業發展趨勢,聚焦具有廣闊增長潛力的輕量化市場,具體業務信息達到披露標準公司會依據信息披露規則要求進行披露。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.